245 related articles for article (PubMed ID: 12226033)
1. The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.
Lamping DL; Schroter S; Marquis P; Marrel A; Duprat-Lomon I; Sagnier PP
Chest; 2002 Sep; 122(3):920-9. PubMed ID: 12226033
[TBL] [Abstract][Full Text] [Related]
2. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
[TBL] [Abstract][Full Text] [Related]
3. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life.
Lamping DL; Schroter S; Kurz X; Kahn SR; Abenhaim L
J Vasc Surg; 2003 Feb; 37(2):410-9. PubMed ID: 12563215
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
8. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia.
Lode H; Grossman C; Choudhri S; Haverstock D; McGivern J; Herman-Gnjidic Z; Church D
Respir Med; 2003 Oct; 97(10):1134-42. PubMed ID: 14561021
[TBL] [Abstract][Full Text] [Related]
9. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia.
El Moussaoui R; Opmeer BC; de Borgie CA; Nieuwkerk P; Bossuyt PM; Speelman P; Prins JM
Chest; 2006 Oct; 130(4):1165-72. PubMed ID: 17035452
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
Torres A; Muir JF; Corris P; Kubin R; Duprat-Lomon I; Sagnier PP; Höffken G
Eur Respir J; 2003 Jan; 21(1):135-43. PubMed ID: 12570122
[TBL] [Abstract][Full Text] [Related]
11. VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis.
Kahn SR; Lamping DL; Ducruet T; Arsenault L; Miron MJ; Roussin A; Desmarais S; Joyal F; Kassis J; Solymoss S; Desjardins L; Johri M; Shrier I;
J Clin Epidemiol; 2006 Oct; 59(10):1049-56. PubMed ID: 16980144
[TBL] [Abstract][Full Text] [Related]
12. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
[TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
14. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia.
Moola S; Hagberg L; Churchyard GA; Dylewski JS; Sedani S; Staley H
Chest; 1999 Oct; 116(4):974-83. PubMed ID: 10531162
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
[TBL] [Abstract][Full Text] [Related]
16. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
Léophonte P; File T; Feldman C
Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
[TBL] [Abstract][Full Text] [Related]
17. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
[TBL] [Abstract][Full Text] [Related]
18. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
19. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
20. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).
Ferrara AM
Clin Interv Aging; 2007; 2(2):179-87. PubMed ID: 18044134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
